Bipartisan Bill H.R. 7391 Would Exempt FQHCs from 340B Rebate Model — 35 Cosponsors
Reps. Auchincloss (D-MA) and Bergman (R-MI) introduced the Community Health Center Drug Pricing Protection Act to exempt FQHCs from HRSA's 340B Rebate Model Pilot Program.
The bill mandates upfront ceiling-price purchasing — no post-purchase reconciliation. Currently has 35 cosponsors. HRSA's RFI on 340B rebates has comments due April 20, 2026.
FQHCs account for 1% of healthcare spending but treat 10% of Americans.
Key takeaways
- Bipartisan bill H.R. 7391 would exempt FQHCs from HRSA's 340B Rebate Model Pilot Program
- Currently has 35 cosponsors — mandates upfront ceiling-price purchasing (no post-purchase reconciliation)
- HRSA's RFI on 340B rebates has comments due April 20, 2026
- FQHCs account for 1% of healthcare spending but treat 10% of Americans
- Action: Submit comments on HRSA RFI before April 20 deadline
Primary source
U.S. House of RepresentativesSource packet
This story's primary source + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — subscribes you to the weekly Intel Brief. Individual sources are always clickable above, no email needed.
FQHC Talent. (2026, February 10). Bipartisan Bill H.R. 7391 Would Exempt FQHCs from 340B Rebate Model — 35 Cosponsors. Primary source: U.S. House of Representatives. Retrieved July 28, 2026, from https://www.fqhctalent.com/intel/hr-7391-340b-fqhc-protection-act
More in Legislation
Jul 24
HHS strips disparate-impact liability out of its Title VI regulations — final rule, effective the day it published, no comment period; 45 CFR part 80 binds every Section 330 grantee
Jul 22
Arkansas AG sues 13 drugmakers + a data firm over 340B — the first time a state goes on OFFENSE under its own 340B shield law, with the state health-center association standing beside him
Jul 16
CY2027 Physician Fee Schedule Proposed Rule Lands — CMS Proposes the FQHC PPS Base Rate Rise to $212.91 (+2.5%), Comments Close September 14
Jul 1
8th Circuit Rejects Novartis's Bid to Block Missouri's 340B Contract-Pharmacy Law — Another State Shield Survives a Manufacturer Challenge